BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Rib-X Pharmaceuticals, Inc. Reports Preclinical Studies at ICAAC With Novel Classes of RX-04 Antibiotic Compounds Demonstrating Potent and Rapid Efficacy in a S. pneumoniae Lung Model of Infection and Activity Against a Diverse Spectrum of Biodefense Pathogens


9/12/2012 10:17:01 AM

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc. announced today the presentation of five posters featuring completely new antibiotic compounds from the company’s RX-04 program at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 9-12, 2012 in San Francisco, CA. The reported data from multiple preclinical studies emphasized the potent, broad spectrum activity of RX-04 compounds, including at single, low doses. A study conducted in a Streptococcus pneumoniae lung infection model established the potential for this class of compounds to address respiratory pathogens. Additionally, studies demonstrated the unique activity of these novel antibiotics across a diverse array of bacterial pathogens, including against carbapenem- and colistin-resistant strains of Klebsiella pneumoniae and five major biodefense pathogens.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES